The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific ...
Cambridge, USA-based clinical-stage biotechnology company Caldera Therapeutics, which is developing the first-in-class ...
Verywell Health on MSN
How Stress Affects IBS-C and Ways to Get Relief
Learn why the gut–brain connection increases stress and affects IBS symptoms and explore evidence-based treatments like ...
During the J.P. Morgan Healthcare Conference, VIVUS will share key highlights from 2025, demonstrating our commitment to advancing innovative clinical therapies across a variety of conditions,” said ...
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
King Faisal Specialist Hospital & Research Centre continues to advance complex transplant medicine through its Intestinal Transplant Program, a highly specialized service designed to manage patients ...
Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 Meaningful non-dilutive capital enables Jaguar to ...
MINNEAPOLIS — A new study published on December 23, 2025, in Neurology ®, the medical journal of the American Academy of Neurology, looks at how age may affect recovery for people with spinal cord ...
According to MarketsandMarkets™, the Human Microbiome Drugs Market is projected to grow from about USD 0.35 billion in 2025 ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback